^
    Back
    Association details:
    Biomarker:DDR
    Cancer:Renal Cell Carcinoma
    Drug Class:Tyrosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GU 2021
    Title:

    DNA damage repair (DDR) pathway alteration in advanced renal cell carcinoma (RCC) is association with good progression-free survival with tyrosine kinase inhibitor (TKI) therapy.

    Published date:
    02/08/2021
    Excerpt:
    ...For patients with TKI treatment, Mut DDR status was associated with superior progression free survival (log-rank p = 0.048)...
    DOI:
    10.1200/JCO.2021.39.6_suppl.346